Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV)
administered twice weekly for the treatment of adenovirus (AdV) infection detected during
asymptomatic AdV viremia or during symptomatic AdV infection.